EmeraMed: who we are…

EmeraMed Limited is a privately held limited liability company (corporation) organized and headquartered in the United States. The Company currently operates in Ireland, Sweden and the United States. The Company’s owner group is primarily composed of physicians, dentists, and patients with personal experience of the product from when it was previously sold as a dietary supplement. If you are interested in learning more about the Company, please use our Contact page to request additional information.

This information is provided for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction.

Emeramide: A unique chelator

Emeramide is a lipophilic di-thiol compound. It has received Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for mercury toxicity. Pre-clinical safety studies have been conducted in multiple species. In addition, a Phase I clinical trial and four Phase II clinical trials have been performed. The company is continuing the development of Emeramide. The goal is to obtain marketing authorization in various regions, including the United States and the European Union.

  • International Non-Proprietary Name (INN): Emeramide

  • Molecule: N,N’-bis(2-mercaptoethyl)isophthalamide (NBMI)

Our research and development efforts are committed to improving the health and well being of people and animals around the world by applying sound principles of medicine and science and working collaboratively with internationally renowned researchers and university centers.

Meet Our Team

Dr. David Kennedy
Dr. David KennedyInterim CEO
Dr. Kennedy earned his Doctor of Dental Surgery from the University of Missouri. He has lectured throughout the world to physicians and dentists about the risks to dental personnel from occupational exposure to mercury.
READ MORE
Boyd Haley, PhD
Boyd Haley, PhDChief Scientist & Board Member
Dr. Haley has lectured throughout the world and testified before Congressional oversight committees and the Institute of Medicine regarding various aspects of mercury toxicity and neurological diseases.
READ MORE
Ragnar Klingberg
Ragnar KlingbergBoard Member
Mr Klingberg has a background in management consulting and as an entrepreneur. He has been with EmeraMed since 2011.
READ MORE
Kathryn Wachsman
Kathryn WachsmanBoard Secretary
Kathryn Wachsman is a practicing attorney with over three decades of experience in legal advocacy including litigation, mediation, negotiation, and legal analysis. She possesses extensive business experience…
READ MORE
Paul Reicherter, MD
Paul Reicherter, MDBoard Member
Paul Reicherter MD, is a graduate of Baker University in Kansas where he was a scholar athlete and Magna Cum Laude graduate. He earned his medical degree at the University of Kansas Medical Center where he graduated with highest honors and was inducted into the Alpha Omega Alpha Honor Medical Society.
READ MORE

Discover The Future of Health

We are committed to advancing the development of Emeramide (also known as Irminix®), a lipophilic di-thiol compound, with a focus on toxicology-related conditions.

Contact Us